U.S., Sept. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07797621) titled 'Phase 1 Study to Evaluate the Safety and Drug-Drug Interactions in Healthy Adult Participants' on Aug. 26.
Brief Summary: This Phase 1 study will evaluate the safety and drug-drug interactions of AG2203L and AG2203E in healthy adult participants. Participants will receive AG2203L and AG2203E alone and in combination during three treatment periods according to one of six randomly assigned treatment sequences.
Study Start Date: March 28, 2025
Study Type: INTERVENTIONAL
Condition:
Acute Bronchitis
Intervention:
DRUG: AG2203L
Multiple doses of 1 tablet three times daily under fasting conditions, followed by a single dose of 1 tab...